Similar articles

• Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?

  Besarab A, McCrea JB. Besarab A, et al. ASAIO J. 1993 Jan-Mar;39(1):11-8. ASAIO J. 1993. PMID: 8439674 Review. No abstract available.
• Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).

  Coyne DW. Coyne DW. Nephrol News Issues. 2013 Feb;27(2):16, 18, 20. Nephrol News Issues. 2013. PMID: 23469454 No abstract available.
• Erythropoietin & ESRD payments: a promising policy outcome?

  Roe W. Roe W. Nephrol News Issues. 1989 Sep;3(9):34-5. Nephrol News Issues. 1989. PMID: 2682270 No abstract available.
• Finding a rational approach to ESA therapy--for payers and patients.

  Messana A. Messana A. Nephrol News Issues. 2007 Sep;21(10):54, 56. Nephrol News Issues. 2007. PMID: 17918481 No abstract available.
• How dialysis is paid for: what the dialysis medical director should know, and why.

  Deoreo PB. Deoreo PB. Semin Dial. 2008 Jan-Feb;21(1):58-62. doi: 10.1111/j.1525-139X.2007.00393.x. Epub 2007 Dec 11. Semin Dial. 2008. PMID: 18086259 Review.